Aclaris sells OLUMIANT royalties to OMERS for up to $31.5M upfront and milestones

Aclaris Therapeutics, Inc.

Received $26.5M upfront; eligible for up to $5M additional based on 2024 sales milestones for OLUMIANT.
Sold portion of future OLUMIANT royalties from Lilly and 100% of remaining anniversary milestone payments.
Non-dilutive transaction; proceeds to strengthen balance sheet and support strategic priorities.
Aclaris continues strategic review; will invest in internal immuno-inflammatory pipeline programs.
OLUMIANT (baricitinib) is Lilly's treatment for alopecia areata; royalty term runs through remainder of license.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.